Skip to main content
SpringerLink
Log in

Mineralocorticoid Disorders and Endocrine Hypertension

  • Chapter
  • First Online:
Pediatric Endocrinology

Abstract

The renin-angiotensin-aldosterone system regulates intravascular volume and the serum potassium concentration through its regulation of sodium and potassium handling in the distal nephron of the kidneys. Isolated disorders of this system in children are rare but when present can cause significant morbidity from either deficient or excess mineralocorticoid action. This chapter describes the physiology of mineralocorticoid action followed by the mechanisms responsible for disordered mineralocorticoid action. For each disorder, the appropriate diagnostic evaluation and treatment recommendations are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rainey W. Adrenal zonation: clues from 11beta-hydroxylase and aldosterone synthase. Mol Cel Endocrinol. 1999;151:151–60.

    Article  CAS  Google Scholar 

  2. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci U S A. 1983;80(19):6056–60.

    Article  CAS  Google Scholar 

  3. Funder JW, Pearce PT, Smith R, Smith AIAN. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242(4878):583–5.

    Article  CAS  Google Scholar 

  4. Funder JW. Apparent mineralocorticoid excess. J Steroid Biochem Mol Biol. 2015;2016:2015–7.

    Google Scholar 

  5. Riepe FG. Pseudohypoaldosteronism. Endocr Dev. 2013;24:86–95.

    Article  CAS  Google Scholar 

  6. Dooley R, Harvey BJ, Thomas W. Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol Cell Endocrinol. 2012;350(2):223–34.

    Article  CAS  Google Scholar 

  7. White PC. Aldosterone synthase deficiency and related disorders. Mol Cell Endocrinol. 2004;217(1–2):81–7.

    Article  CAS  Google Scholar 

  8. Geller DS, Rodriguez-Soriano J, Vallo Boado A, Schifter S, Bayer M, Chang SS, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet. 1998;19(3):279–81.

    Article  CAS  Google Scholar 

  9. Riepe FG, Finkeldei J, De Sanctis L, Einaudi S, Testa A, Karges B, et al. Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J Clin Endocrinol Metab. 2006;91(11):4552–61.

    Article  CAS  Google Scholar 

  10. Chang SS, Grunder S, Hanukoglu A, Rösler A, Mathew PM, Hanukoglu I, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet. 1996;12(3):248–53.

    Article  CAS  Google Scholar 

  11. Bogdanović R, Stajić N, Putnik J, Paripović A. Transient type 1 pseudo-hypoaldosteronism: report on an eight-patient series and literature review. Pediatr Nephrol. 2009;24(11):2167–75.

    Article  Google Scholar 

  12. Deppe CE, Heering PJ, Viengchareun SAY, Grabensee B, Farman N, Lombes M. Cyclosporine A and FK506 inhibit transcriptional activity of the human mineralocorticoid receptor: a cell-based model to investigate partial aldosterone resistance in kidney transplantation. Endocrinology. 2002;143(5):1932–41.

    Article  CAS  Google Scholar 

  13. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–916.

    Article  CAS  Google Scholar 

  14. Korah HE, Scholl UI. An update on familial hyperaldosteronism. Horm Metab Res. 2015;47(13):941–6.

    Article  CAS  Google Scholar 

  15. Scholl UI, Healy JM, Thiel A, Fonseca AL, Brown TC, Kunstman JW, et al. Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clin Endocrinol. 2015;83(6):779–89.

    Article  CAS  Google Scholar 

  16. Gatta-Cherifi B, Chabre O, Murat A, Niccoli P, Cardot-Bauters C, Rohmer V, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d’étude des Tumeurs Endocrines database. Eur J Endocrinol. 2012;166(2):269–79.

    Article  CAS  Google Scholar 

  17. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293–300.

    Article  CAS  Google Scholar 

  18. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab. 2008;93(8):3117–23.

    Article  CAS  Google Scholar 

  19. Mussa A, Camilla R, Monticone S, Porta F, Tessaris D, Verna F, et al. Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. Endocr J. 2012;59(6):497–502.

    Article  CAS  Google Scholar 

  20. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90(9):5070–6.

    Article  CAS  Google Scholar 

  21. Milliez P, Girerd X, Plouin P-F, Blacher J, Safar ME, Mourad J-J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243–8.

    Article  CAS  Google Scholar 

  22. Shera AH, Baba AA, Bakshi IH, Lone IA. Recurrent malignant juxtaglomerular cell tumor: a rare cause of malignant hypertension in a child. J Indian Assoc Pediatr Surg. 2011;16(4):152–4.

    Article  Google Scholar 

  23. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355(6357):262–5.

    Article  CAS  Google Scholar 

  24. Dluhy RG, Anderson B, Harlin B, Ingelfinger J, Lifton R. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr. 2001;138(5):715–20.

    Article  CAS  Google Scholar 

  25. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension. 1998;31(1 Pt 2):445–50.

    Article  CAS  Google Scholar 

  26. New MI, Geller DS, Fallo F, Wilson RC, Quinkler M, et al. Monogenic low renin hypertension. Trends Endocrinol Metab. 2005;16(3):92–7.

    Article  CAS  Google Scholar 

  27. Moudgil A, Rodich G, Jordan SC, Kamil ES. Nephrocalcinosis and renal cysts associated with apparent mineralocorticoid excess syndrome. Pediatr Nephrol. 2000;15(1–2):60–2.

    Article  CAS  Google Scholar 

  28. Ferrari P. The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim Biophys Acta. 2010;1802(12):1178–87.

    Article  CAS  Google Scholar 

  29. Sontia B, Mooney J, Gaudet L, Touyz RM. Pseudohyperaldosteronism, liquorice, and hypertension. J Clin Hypertens (Greenwich). 2008;10(2):153–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    David W. Cooke

Authors
  1. David W. Cooke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David W. Cooke .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

    Sally Radovick

  2. Pediatric Endocrinology, Massachusetts General Hospital for Children, Boston, Massachusetts, USA

    Madhusmita Misra

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cooke, D.W. (2018). Mineralocorticoid Disorders and Endocrine Hypertension. In: Radovick, S., Misra, M. (eds) Pediatric Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-73782-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-73782-9_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-73781-2

  • Online ISBN: 978-3-319-73782-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation